Teva to terminate ADS program; ADSs exchange for NYSE-listed ordinary shares on Sept 14, 2026

TEVA PHARMACEUTICAL INDUSTRIES LTD

Amendment No. 1 to deposit agreement executed Aug 31, 2026; each ADS exchanges for one ordinary share.
ADS program termination effective at open of business Sept 14, 2026; all outstanding ADSs cancelled.
Ordinary shares will be listed on NYSE; ADS holders become direct shareholders of Teva.
Depositary Citibank, N.A. involved; ADR form updated accordingly.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.